C4 Therapeutics (CCCC) Accumulated Expenses (2019 - 2025)
Historic Accumulated Expenses for C4 Therapeutics (CCCC) over the last 7 years, with Q3 2025 value amounting to $11.3 million.
- C4 Therapeutics' Accumulated Expenses fell 2676.11% to $11.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.3 million, marking a year-over-year decrease of 2676.11%. This contributed to the annual value of $19.4 million for FY2024, which is 614.15% down from last year.
- Per C4 Therapeutics' latest filing, its Accumulated Expenses stood at $11.3 million for Q3 2025, which was down 2676.11% from $13.6 million recorded in Q2 2025.
- C4 Therapeutics' Accumulated Expenses' 5-year high stood at $20.6 million during Q4 2023, with a 5-year trough of $6.3 million in Q1 2021.
- For the 5-year period, C4 Therapeutics' Accumulated Expenses averaged around $14.3 million, with its median value being $13.6 million (2021).
- As far as peak fluctuations go, C4 Therapeutics' Accumulated Expenses soared by 7179.62% in 2022, and later tumbled by 3303.25% in 2024.
- Quarter analysis of 5 years shows C4 Therapeutics' Accumulated Expenses stood at $13.6 million in 2021, then skyrocketed by 45.3% to $19.8 million in 2022, then increased by 4.36% to $20.6 million in 2023, then dropped by 6.14% to $19.4 million in 2024, then plummeted by 41.8% to $11.3 million in 2025.
- Its last three reported values are $11.3 million in Q3 2025, $13.6 million for Q2 2025, and $12.6 million during Q1 2025.